T-type voltage-gated calcium channel (T-type VGCC)

T-type voltage-gated calcium channels (VGCCs) are a distinct class of low-voltage-activated (LVA) channels that open in response to small membrane depolarizations near the resting potential (UniProt, 2024). They are characterized by their "tiny" (T-type) single-channel conductance and "transient" opening kinetics, playing a fundamental role in regulating rhythmic burst firing and pacemaker activity in both the central nervous system and the heart (PubMed, 2021). The family consists of three subtypes—Cav3.1, Cav3.2, and Cav3.3—which are encoded by the CACNA1G, CACNA1H, and CACNA1I genes, respectively (NCBI, 2022). Dysfunction or over-expression of these channels is strongly associated with the pathogenesis of absence epilepsy, neuropathic pain, and certain cardiac arrhythmias (StatPearls, 2023). Pharmacologically, these channels are the primary target for anti-absence seizure medications like ethosuximide, and they are increasingly investigated as targets for treating chronic pain, sleep disturbances, and movement disorders (Nature Reviews Drug Discovery, 2020). Their unique ability to operate at sub-threshold voltages makes them critical for fine-tuning neuronal excitability and oscillatory behavior in thalamocortical circuits.

Other names

Low-voltage-activated calcium channelLVA calcium channelCav3Cav3.1Cav3.2Cav3.3CACNA1GCACNA1HCACNA1I

T-type calcium channel blockers inhibit the influx of calcium ions by binding to the alpha-1 pore-forming subunit (Cav3.1, Cav3.2, or Cav3.3), typically stabilizing the inactivated state of the channel or physically occluding the pore during low-voltage membrane depolarizations (PubMed, 2021; StatPearls, 2023).